The clinical evaluation of hepatoblastoma includes several well-established prognostic factors, such as the presence of metastatic disease at diagnosis, the pre-treatment extent of the tumor (PRETEXT stage), histological subtypes, and serum alpha-fetoprotein (AFP) levels [3,4,5]. The gene discussed is AFP; the disease is metastatic neoplasm.